Literature DB >> 29653445

Revision Anterior Cruciate Ligament Reconstruction Outcomes at a Minimum of 5-Year Follow-Up: A Systematic Review.

Rick W Wright1, Lea Johnson1, Robert H Brophy1, Ljiljana Bogunovic1, Matthew J Matava1, Matthew V Smith1.   

Abstract

Revision anterior cruciate ligament (ACL) reconstruction typically has worse outcomes than primary reconstructions. Minimal long-term data exist regarding 5-year results. We chose to perform a systematic review to evaluate midterm (5-year) revision ACL reconstruction outcomes (patient-reported outcomes, reoperation, stability, arthritis) in comparison to primary ACL reconstructions at similar time points. Embase, Cochrane, and PubMed databases were queried, and four studies met the inclusion criteria. Two authors reviewed and performed data extraction. All were level 4 studies. Review of the studies demonstrated that results at 5 years are consistently worse than those noted in primary reconstructions for objective and patient-reported outcomes. Revision ACL reconstruction outcomes remain worse than primary reconstructions at midterm 5-year follow-up. The level of evidence is 4. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2018        PMID: 29653445     DOI: 10.1055/s-0038-1641137

Source DB:  PubMed          Journal:  J Knee Surg        ISSN: 1538-8506            Impact factor:   2.757


  3 in total

Review 1.  Predictors of clinical outcome following revision anterior cruciate ligament reconstruction.

Authors: 
Journal:  J Orthop Res       Date:  2020-01-14       Impact factor: 3.494

2.  [Clinical application of slope-reducing tibial osteotomy and anterior cruciate ligament revision in patients with abnormally increased posterior tibial slope].

Authors:  Gang Li; Xuebin Sun; Keyuan Zhang; Yang Liu
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-01-15

3.  Association Between Graft Choice and 6-Year Outcomes of Revision Anterior Cruciate Ligament Reconstruction in the MARS Cohort.

Authors:  Rick W Wright; Laura J Huston; Amanda K Haas; Jacquelyn S Pennings; Christina R Allen; Daniel E Cooper; Thomas M DeBerardino; Warren R Dunn; Brett Brick A Lantz; Kurt P Spindler; Michael J Stuart; John P Albright; Annunziato Ned Amendola; Jack T Andrish; Christopher C Annunziata; Robert A Arciero; Bernard R Bach; Champ L Baker; Arthur R Bartolozzi; Keith M Baumgarten; Jeffery R Bechler; Jeffrey H Berg; Geoffrey A Bernas; Stephen F Brockmeier; Robert H Brophy; Charles A Bush-Joseph; J Brad Butler V; John D Campbell; James L Carey; James E Carpenter; Brian J Cole; Jonathan M Cooper; Charles L Cox; R Alexander Creighton; Diane L Dahm; Tal S David; David C Flanigan; Robert W Frederick; Theodore J Ganley; Elizabeth A Garofoli; Charles J Gatt; Steven R Gecha; James Robert Giffin; Sharon L Hame; Jo A Hannafin; Christopher D Harner; Norman Lindsay Harris; Keith S Hechtman; Elliott B Hershman; Rudolf G Hoellrich; David C Johnson; Timothy S Johnson; Morgan H Jones; Christopher C Kaeding; Ganesh V Kamath; Thomas E Klootwyk; Bruce A Levy; C Benjamin Ma; G Peter Maiers; Robert G Marx; Matthew J Matava; Gregory M Mathien; David R McAllister; Eric C McCarty; Robert G McCormack; Bruce S Miller; Carl W Nissen; Daniel F O'Neill; Brett D Owens; Richard D Parker; Mark L Purnell; Arun J Ramappa; Michael A Rauh; Arthur C Rettig; Jon K Sekiya; Kevin G Shea; Orrin H Sherman; James R Slauterbeck; Matthew V Smith; Jeffrey T Spang; Ltc Steven J Svoboda; Timothy N Taft; Joachim J Tenuta; Edwin M Tingstad; Armando F Vidal; Darius G Viskontas; Richard A White; James S Williams; Michelle L Wolcott; Brian R Wolf; James J York
Journal:  Am J Sports Med       Date:  2021-07-14       Impact factor: 7.010

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.